05/18/2022 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Icon check
05/13/2022 Number of shares and voting rights of ADOCIA as of April 30th, 2022 Icon check
05/09/2022 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao Icon check
04/25/2022 ADOCIA Announces the Release of its Universal Registration Document for the Year 2021 Icon check
04/19/2022 ADOCIA announces its annual results for 2021 and presents an update on activities Icon check
04/15/2022 Number of shares and voting rights of ADOCIA as of March 31st, 2022 Icon check
04/11/2022 ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao Icon check
03/28/2022 Adocia strengthens its cash position by 19 million euros following a real estate transaction Icon check
03/16/2022 Number of shares and voting rights of ADOCIA as of February 28th, 2022 Icon check
02/23/2022 ADOCIA announces 2021 fourth quarter financial results Icon check
02/15/2022 Number of shares and voting rights of ADOCIA as of January 31st, 2021 Icon check
01/11/2022 Number of shares and voting rights of ADOCIA as of December 31st, 2021 Icon check
01/06/2022 ADOCIA announces its financial calendar for 2022 Icon check
12/20/2021 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 Icon check
12/15/2021 Number of shares and voting rights of ADOCIA as of November 30th, 2021 Icon check
12/13/2021 Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides Icon check
11/19/2021 Number of shares and voting rights of ADOCIA as of October 31st, 2021 Icon check
10/26/2021 Adocia announces 2021 third quarter financial results and a financing of €7 million Icon check
10/14/2021 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China Icon check
10/12/2021 Number of shares and voting rights of ADOCIA as of September 30th, 2021 Icon check
09/21/2021 ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD Icon check
09/13/2021 Number of shares and voting rights of ADOCIA as of August 31st, 2021 Icon check
09/10/2021 Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Icon check
09/07/2021 ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities Icon check
08/23/2021 Number of shares and voting rights of ADOCIA as of July 31st, 2021 Icon check
07/29/2021 Bilan Semestriel du contrat de liquidité Adocia conclu avec la société Kepler Capital Markets
07/22/2021 ADOCIA Announces Second Quarter 2021 Financial Results Icon check
07/15/2021 Number of shares and voting rights of ADOCIA as of June 30th, 2021 Icon check
06/29/2021 ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes Icon check
06/27/2021 ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.
06/15/2021 ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions Icon check
06/10/2021 Number of shares and voting rights of ADOCIA as of May 31st, 2021 Icon check
06/08/2021 ADOCIA confirms its eligibility for the PEA–PME Icon check
06/02/2021 ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes, Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.
06/02/2021 ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021 Icon check
06/01/2021 ADOCIA reinforces its board of directors with the appointment of three new independent members. Icon check
05/26/2021 ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps Icon check
05/17/2021 Number of shares and voting rights of ADOCIA as of April 30, 2021 Icon check
05/11/2021 ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 Icon check
04/23/2021 ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970. Icon check
04/21/2021 ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 Icon check
04/21/2021 ADOCIA Announces First Quarter 2021 Financial Results Icon check
04/19/2021 ADOCIA: Number of shares and voting rights of ADOCIA as of March 31st, 2021 Icon check
03/18/2021 ADOCIA Announces Financial Results 2020 And Provides Corporate Update. Icon check
03/17/2021 Number of shares and voting rights of ADOCIA as of February 28th, 2021 Icon check
03/10/2021 Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes Icon check
02/16/2021 Number of shares and voting rights of ADOCIA as of January 31, 2021 Icon check
01/25/2021 Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao Icon check
01/20/2021 Number of shares and voting rights of ADOCIA as of December 31, 2020 Icon check
01/18/2021 Adocia Announces half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
01/11/2021 Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes Icon check
12/21/2020 Adocia announces its financial calendar for 2021 Icon check
12/07/2020 Number of shares and voting rights of ADOCIA as of November 30, 2020 Icon check
11/06/2020 Number of shares and voting rights of ADOCIA as of October 31, 2020 Icon check
10/20/2020 Adocia Announces Third Quarter 2020 Financial Results Icon check
10/09/2020 Number of shares and voting rights of ADOCIA as of September 30, 2020 Icon check
09/22/2020 Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020 Icon check
09/15/2020 Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes. Icon check
09/10/2020 ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr.  Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.
09/08/2020 Number of shares and voting rights of ADOCIA as of August 31, 2020 Icon check
Join our mailing list. Subscribe